Corporation
AstraZeneca Canada Inc.
- Meetings this Parliament
- 63
- With MPs
- 19
- Since Nov 2021
- 134
- Active registrations
- 1
Most recent reported meeting: Aug 28, 2026.
Lobbying by AstraZeneca Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since May 11, 2026
Filed by Gaby Bourbara, President
Lobbyists
- Alex Romanovschi · Vice President, Scientific Affairs
- Carlo Mastrangelo · Head - Corporate Communications - Corporate Affairs Canada
- Deb Wong · Director, Payer Engagement
- Denise Lacombe · Head of Legal
- Gena Restivo · VP, Corporate Affairs & Sustainability
- Heather McDonald · Vice President, Market Access and Pricing
- Isabelle Gagnon · Lead - Federal Government Affairs
- Jon Feairs · Director, Government Affairs & Public Policy
- Noel Saraza · Senior Manager, Payer Relations
- Pascal Soriot · Chief Executive
- Tharany Ganesh · Head of Regulatory Affairs
Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Atlantic Canada Opportunities Agency (ACOA), Canada Economic Development for Quebec Regions, Canada Foundation for Innovation, Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Canadian International Trade Tribunal (CITT), Canadian Northern Economic Development Agency (CanNor), Competition Bureau Canada (COBU), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), International Development Research Centre (IDRC), National Defence (DND), National Research Council (NRC), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Royal Canadian Mounted Police (RCMP), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (14)Hide details
- Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV
- Federally-funded public drug plans, including the Non-Insured Health Benefits program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries
- Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework
- Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
- Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes
- Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
- Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
- Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
- Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
- Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
- Annual federal Budgets and Budget updates relating to the biopharmaceutical industry.
- Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.
Registration 957438-15042-67. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Gaby Bourbara (91), Kiersten Combs (43).
-
Reported by Gaby Bourbara · In-house (corporation)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Engagement with the Government regarding the Strategic Innovation Fund (SIF) and investment in Canada.
-
Reported by Gaby Bourbara · In-house (corporation)
- Samir Khan · Associate Executive Director, Health Canada (HC)
Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance. Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Engagement with the Government regarding the Strategic Innovation Fund (SIF) and investment in Canada. Read more
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry
-
Reported by Gaby Bourbara · In-house (corporation)
- Michael Mosier · Senior Director, Finance Canada (FIN)
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Jay Allen · Minister (Economic), Global Affairs Canada (GAC)
- Kaitlyn Pritchard · Trade Program Manager, Innovation & Industrial Policy, Global Affairs Canada (GAC)
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry Read more
Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance.
-
Reported by Gaby Bourbara · In-house (corporation)
- Galen Richardson · Senior Advisor, Stakeholder Relations, Global Affairs Canada (GAC)
- Miro Froehlich · Director of Policy, Global Affairs Canada (GAC)
- Nasser Haidar · Senior Policy Advisor, Global Affairs Canada (GAC)
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Alexandre Boulé · Senior Advisor, Prime Minister's Office (PMO)
- Shaili Patel · Deputy Director of Policy, Prime Minister's Office (PMO)
Engagement with the Government regarding the Strategic Innovation Fund (SIF) and investment in Canada. Read more
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry
-
Reported by Gaby Bourbara · In-house (corporation)
- Mélanie Joly · Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry Read more
Engagement with the Government regarding the Strategic Innovation Fund (SIF) and investment in Canada.
-
Reported by Gaby Bourbara · In-house (corporation)
- Sandenga Yeba · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance. Read more
Engagement with the Government regarding the Strategic Innovation Fund (SIF) and investment in Canada.
-
Reported by Gaby Bourbara · In-house (corporation)
- Kasondra White · Director General, Innovation, Science and Economic Development Canada (ISED)
- Heather Earle · Deputy Director, Innovation, Science and Economic Development Canada (ISED)
Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as COVID-19 and RSV. Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Director for Innovation, Science and Economic Development, Innovation, Science and Economic Development Canada (ISED)
Engagement with the Government regarding the Strategic Innovation Fund (SIF) and investment in Canada.
-
Reported by Gaby Bourbara · In-house (corporation)
- Cynthia Colapinto · Director, Policy and Data Division, Health Canada (HC)
- Ursula Polack · Senior Advisor, Health Canada (HC)
Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance. Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Samir Khan · Associate Executive Director, Health Canada (HC)
Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance. Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Patrick Halley · Assistant Deputy Minister, Finance Canada (FIN)
- Gabriel Williams · Analyst, Finance Canada (FIN)
Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits. Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Marc-Andre Blais · Senior Investment Manager, Innovation, Science and Economic Development Canada (ISED)
- Robin Kirkpatrick · Senior Investment Analyst, Innovation, Science and Economic Development Canada (ISED)
Updates to, and implementation of, the Biomanufacturing and Life Sciences Strategy to support investments in Canada.
-
Reported by Gaby Bourbara · In-house (corporation)
- Samuel Millar · Assistant Deputy Minister, Finance Canada (FIN)
- Mallika Nanduri Bhatt · Associate Assistant Deputy Minister, Finance Canada (FIN)
Updates to, and implementation of, the Biomanufacturing and Life Sciences Strategy to support investments in Canada.
-
Reported by Gaby Bourbara · In-house (corporation)
- Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Director for Innovation, Science and Economic Development, Innovation, Science and Economic Development Canada (ISED)
Updates to, and implementation of, the Biomanufacturing and Life Sciences Strategy to support investments in Canada.
-
Reported by Gaby Bourbara · In-house (corporation)
- François-Philippe Champagne · Minister, Innovation, Science and Economic Development Canada (ISED)
- Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Laurel Chester · Sr Advisor, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Updates to, and implementation of, the Biomanufacturing and Life Sciences Strategy to support investments in Canada.
-
Reported by Gaby Bourbara · In-house (corporation)
- Carlos Pena · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
HealthIndustry
-
Reported by Gaby Bourbara · In-house (corporation)
- Valerie Bradford · Member of Parliament, House of Commons
HealthIndustry
-
Reported by Gaby Bourbara · In-house (corporation)
- Peter Fragiskatos · Member of Parliament
HealthIndustry
-
Reported by Gaby Bourbara · In-house (corporation)
- Matt Jeneroux · Member of Parliament
HealthIndustry
-
Reported by Gaby Bourbara · In-house (corporation)
- Jean-Denis Garon · Member of Parliament
HealthIndustryResearch and Development
-
Reported by Gaby Bourbara · In-house (corporation)
- Pierre Paul-Hus · Member of Parlliament
- Aymeline Slama · Constituency Assistant, House of Commons
IndustryResearch and Development
-
Reported by Gaby Bourbara · In-house (corporation)
- Eshan Naik · Director of Policy, Health Canada (HC)
Economic DevelopmentResearch and Development
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.